Andrx divested Fortamet® and Altoprev® to the First Horizon Pharmaceutical. The deal is a sensible move for Andrx, as it helps the company to triumph over its losses. Since Fortamet® and Altoprev® are in an incredibly competitive and densely populated market and neither has made any significant impact so far First Horizon intends to promote the products through an expanded sales force. It remains to be seen whether Horizon will succeed in its approach.